Results 201 to 210 of about 75,141 (290)

Issue Information

Experimental Physiology, Volume 111, Issue 5, Page 2731-2735, 1 May 2026.
wiley   +1 more source

MetALD: Diagnosis and Prognosis With Non-Invasive Tests. [PDF]

Aliment Pharmacol Ther
Torp N, Israelsen M, Johansen S, Semmler G, Dalby Hansen C, Bech KT, Andersen ML, Thorhauge KH, Andersen P, Schnefeld HL, Hansen JK, Jensen EL, Hansen ED, Villesen I, Lindvig KP, Leeming DJ, Karsdal M, Tsochatzis EA, Thiele M, Krag A.   +19 more
europepmc   +1 more source

Doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis-leave no one behind: author's reply. [PDF]

Lancet Reg Health Eur
Lazarus JV, Alazawi W, Byrne CD, Caussy C, Brennan PN.   +4 more
europepmc   +1 more source

Implementation of noninvasive liver disease screening tools in primary care. [PDF]

Korean J Fam Med
Nowak K, Nowak A, Jabłońska A, Potaczek A, Salacha J, Dardzińska N, Janczura J.   +6 more
europepmc   +1 more source

Risk Assessment and Prediction of Hepatocellular Carcinoma in Noncirrhotic Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Int J Mol Sci
Mitten EK, Portincasa P, Baffy G.
europepmc   +1 more source

[Non-invasive evaluation and prediction of portal hypertension: focusing on disease progression and outcome]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Xu PS, Wang MC, Chen JJ, Wang HY.
europepmc   +1 more source

Advances and Perspectives in Gate Dielectric Thin Films for 4H-SiC MOSFETs. [PDF]

Materials (Basel)
Bai Z, Liang J, Ding C, Zhou Z, Luo M, Gu L, Ma HP, Zhang QC.   +7 more
europepmc   +1 more source

Opportunistic case-finding of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) by leveraging integrated care pathways of type 2 diabetes. [PDF]

Hepatobiliary Surg Nutr
Makary A, Rojo D, Pagès L, Sabiote C, Jiménez-Masip A, Pericàs JM.   +5 more
europepmc   +1 more source

Towards early detection and prevention: proactive screening strategies in primary care. [PDF]

Korean J Fam Med
Cho SH.
europepmc   +1 more source

Noninvasive prediction of clinically significant portal hypertension in metabolic dysfunction-associated steatotic liver disease compared to other chronic liver diseases. [PDF]

World J Hepatol
Masood M, Thandassery RB.
europepmc   +1 more source